
|Articles|April 1, 2010
Hypertension drug approved for pediatric patients
Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.
Advertisement
Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.
The recommended starting dose is 10 mg once daily for patients who weigh 20 kg to less than 35 kg and 20 mg once daily for patients who weigh at least 35 kg. After 2 weeks, the dose can be increased to a maximum of 20 mg once daily in those who weigh less than 35 kg and 40 mg once daily in those who weigh at least 35 kg.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FAQ: What does the new AAP iron deficiency guidance mean for your practice?
2
CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak
3
What pediatricians should know for the upcoming respiratory virus season
4
Treatment choice for pediatric anxiety may depend on preference and access
5





